Kepičová Markéta, Tulinský Lubomír, Kondé Adéla, Dzurňáková Paula, Ihnát Peter, Adamica Dávid, Neoral Čestmír, Martínek Lubomír
Department of Surgery, University Hospital Ostrava, 17. listopadu 1790, 708 52 Ostrava, Czech Republic.
Department of Surgical Studies, Faculty of Medicine, University of Ostrava, Syllabova 19, 703 00 Ostrava, Czech Republic.
Medicina (Kaunas). 2024 Dec 20;60(12):2088. doi: 10.3390/medicina60122088.
: Postoperative pneumonia and complications significantly impact outcomes in thoracic surgery, particularly for patients undergoing lobectomy for non-small cell lung cancer (NSCLC). This study evaluates whether preoperative premedication influences the risk of postoperative pneumonia and overall complications. : This retrospective study included 346 patients who underwent lobectomy for NSCLC at the University Hospital Ostrava between 2015 and 2021. Data on demographic variables, tumour staging, surgical approach, and premedication (anticholinergics, benzodiazepines, antihistamines, and analgesics) were analysed. Postoperative outcomes included pneumonia and complications classified by the modified Clavien-Dindo system. : Premedication was not significantly associated with postoperative pneumonia (10.7%) or overall complications (26.0%). Tumour size was the only factor significantly associated with complications, with larger tumours increasing the odds (OR: 1.16, = 0.032). Other factors, including age, ASA classification, BMI, and surgical approach, did not demonstrate significant associations with postoperative outcomes. : Premedication does not appear to significantly influence the risk of postoperative pneumonia or overall complications in patients undergoing lobectomy for NSCLC. Similarly, other clinical variables, such as age, ASA classification, BMI, and surgical approach, also did not show significant associations with these outcomes. These findings suggest that premedication can be individualised without increasing postoperative risks. However, tumour size emerged as a significant factor associated with complications, highlighting the need for careful preoperative assessment and planning, particularly in patients with larger tumours.
术后肺炎和并发症对胸外科手术的预后有显著影响,对于接受非小细胞肺癌(NSCLC)肺叶切除术的患者尤为如此。本研究评估术前用药是否会影响术后肺炎风险和总体并发症。:这项回顾性研究纳入了2015年至2021年间在俄斯特拉发大学医院接受NSCLC肺叶切除术的346例患者。分析了人口统计学变量、肿瘤分期、手术方式和术前用药(抗胆碱能药物、苯二氮䓬类药物、抗组胺药和镇痛药)的数据。术后结局包括根据改良Clavien-Dindo系统分类的肺炎和并发症。:术前用药与术后肺炎(10.7%)或总体并发症(26.0%)无显著相关性。肿瘤大小是与并发症显著相关的唯一因素,肿瘤越大,几率越高(OR:1.16, = 0.032)。其他因素,包括年龄、美国麻醉医师协会(ASA)分级、体重指数(BMI)和手术方式,与术后结局无显著相关性。:术前用药似乎不会显著影响接受NSCLC肺叶切除术患者的术后肺炎风险或总体并发症。同样,其他临床变量,如年龄、ASA分级、BMI和手术方式,也与这些结局无显著相关性。这些发现表明,术前用药可以个体化,而不会增加术后风险。然而,肿瘤大小是与并发症相关的一个重要因素,这突出了术前仔细评估和规划的必要性,特别是对于肿瘤较大的患者。